<DOC>
<DOCNO>EP-0644196</DOCNO> 
<TEXT>
<INVENTION-TITLE>
TTTr as a protecting group in nucleotide synthesis
</INVENTION-TITLE>
<CLASSIFICATIONS>C07H1904	C07H2104	C07H1900	C07H1906	C07H2100	C07H1916	C07H2100	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07H	C07H	C07H	C07H	C07H	C07H	C07H	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07H19	C07H21	C07H19	C07H19	C07H21	C07H19	C07H21	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
The present invention relates to nucleosides, nucleotides and oligonucleotides whose basic structure contains a primary hydroxyl group protected by tris-4,4',4''-tert-butylphenylmethyl, to processes for the preparation of these nucleosides and nucleotides, to a process for preparing oligonucleotides, and to the use of such protected nucleosides, nucleotides and oligonucleotides.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
CIBA GEIGY AG
</APPLICANT-NAME>
<APPLICANT-NAME>
NOVARTIS AG
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BRILL WOLFGANG K D DR
</INVENTOR-NAME>
<INVENTOR-NAME>
BRILL, WOLFGANG K. D., DR.
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide comprising at least two 

such identical or different nucleotides and/or nucleotide 
analogs, whose parent structure comprises an unsubstituted 

or substituted residue of a nucleobase B and one 
primary, protected hydroxyl group, wherein the protective 

group is tris-4,4',4''-tert-butyltrityl. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 1, 

which is additionally protected by an amidine protective 
group or by a cycloalkylcarbonyl group which contains 3 

to 12 ring carbon atoms and which is unsubstituted or 
substituted by C
1
-C
6
alkyl or C
1
-C
6
alkoxy. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 2, 

wherein the cycloalkylcarbonyl group contains 4 to 8 ring 
carbon atoms. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 3, 

wherein the cycloalkylcarbonyl group contains 5 or 6 ring 
carbon atoms. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide accordi
ng to claim 4, 
wherein the cycloalkylcarbonyl group is cyclohexanecarbonyl.  

 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 1, 

wherein the nucleobase B is a radical of formula I, Ia, 
Ib, Ic, Id or Ie 


 
wherein R
1
 is H, Cl, Br, NH
2
 or OH, and R
2
, R
3
 and R
4
 are 
each independently of one another H, OH, SH, NH
2
, NHNH
2
, 
NHOH, NHOalkyl containing 1 to 12 carbon atoms, F, Cl, 

Br, alkyl or hydroxyalkyl or aminoalkyl or alkoxy or 
alkylthio of 1 to 12 carbon atoms, where the hydroxyl and 

amino groups are unsubstituted or substituted by a 
protective group, or are phenyl, benzyl, primary amino 

containing 1 to 20 carbon atoms or secondary amino 
containing 2 to 30 carbon atoms, and R
5
 is H or 
C
1
-C
4
alkyl. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 6, 

wherein the primary amino contains 1 to 12 carbon atoms 
and the secondary amino contains 2 to 12 carbon atoms. 
A nucleoside, nucleoside analog, nucleotide, nucleotide  
 

analog or oligonucleotide according to claim 6, 
wherein the primary amino and secondary amino are radicals 

of formula R
6
R
7
N, wherein R
6
 is H or independently 
has the meaning of R
7
, and R
7
 is C
1
-C
20
alkyl, C
1
-C
20
aminoalkyl, 
C
1
-C
20
hydroxyalkyl; carboxyalkyl or carbalkoxyalkyl 
in which the carbalkoxy moiety contains 2 to 8 carbon 

atoms and the alkyl moiety contains 1 to 6 carbon atoms; 
C
2
-C
20
alkenyl; phenyl, mono- or di(C
1
-C
4
alkyl- or 
-alkoxy)phenyl, benzyl, mono- or di(C
1
-C
4
alkyl- or 
-alkoxy)benzyl; or 1,2-, 1,3- or 1,4-imidazolyl-C
1
-C
6
alkyl, 
or R
6
 and R
7
, taken together, are tetra- or 
pentamethylene, 3-oxa-1,5-pentylene, -CH
2
-NR
8
-CH
2
CH
2
- or 
-CH
2
CH
2
-NR
8
-CH
2
CH
2
-, wherein R
8
 is H or C
1
-C
4
alkyl, and the 
amino group in the aminoalkyl is unsubstituted or substituted 

by one or two C
1
-C
4
alkyl or C
1
-C
4
hydroxyalkyl 
groups, and the hydroxyl group in the hydroxyalkyl is 

free or etherified with C
1
-C
4
alkyl. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 7, 

wherein the primary amino and secondary amino are methylamino, 
ethylamino, dimethylamino, diethylamino, allylamino, 

mono- or di(hydroxyeth-2-yl)amino, phenylamino, 
benzylamino, acetylamino, isobutyrylamino and benzoylamino. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 6, 

wherein R
1
 in formulae I, Ib, Ic, Id and Ie is hydrogen. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 6, 

wherein R
4
 in formula Id is hydrogen. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 6, 

wherein R
2
 and R
3
 in formulae I, Ia, Ib, Ic, Id and Ie 
are each independently of the other H, F, Cl, Br, OH, SH, 

NH
2
, NHOH, NHNH
2
, methylamino, dimethylamino, benzoylamino,  
 

methoxy, ethoxy and methylthio. 
A nucleoside, nucleoside analog, nucleotide, nucleotide 
analog or oligonucleotide according to claim 6, 

wherein B is a purine radical or the radical of a purine 
analog from the series consisting of adenine, N-methyladenine, 

N-benzoyladenine, 2-methylthioadenine, 2-aminoadenine, 
2-hydroxypurine, 2-amino-6-chloropurine, 2-amino-6-methylthiopurine, 

guanine and N-isobutyrylguanine. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

1, wherein the nucleobase B is a radical of formula II, 
IIa or IIb 


 
wherein R
5
 is H or C
1
-C
4
alkyl and R
6
, R
7
 and R
9
 each 
independently of one another are H, OH, SH, NH
2
, NHNH
2
, 
NHOH, NHOalkyl containing 1 to 12 carbon atoms, F, Cl, 

Br, alkyl or hydroxyalkyl or aminoalkyl or alkoxy or 
alkylthio containing 1 to 12 carbon atoms, where the 

hydroxyl and amino groups are unsubstituted or substituted 
by a protective group, or are phenyl, benzyl, 

primary amino containing 1 to 20 carbon atoms or secondary 
amino containing 2 to 30 carbon atoms, and the 

hydrogen atoms of the NH
2
 group in formula IIb may be  
 

substituted by C
1
-C
6
alkyl or benzoyl, or a dihydro 
derivative thereof. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

14, wherein R
6
 is H, C
1
-C
6
alkyl or C
1
-C
6
hydroxyalkyl, F, 
Cl, Br, NH
2
, benzoylamino, mono- or di-C
1
-C
6
alkylamino. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

14, wherein R
7
 is H, C
1
-C
6
alkyl or C
1
-C
6
alkoxy or C
1
-C
6
-hydroxyalkyl, 
F, Cl, Br, NH
2
, benzoylamino, mono- or di-C
1
-C
6
alkylamino. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

16, wherein R
7
 is H, F, Cl, Br, NH
2
, NHCH
3
, N(CH
3
)
2
 or 
C
1
-C
4
alkyl. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

16, wherein R
7
 is H, C
1
-C
4
alkyl, NH
2
, NHCH
3
 or (CH
3
)
2
N. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

14, wherein B is a pyrimidine radical or a radical of a 
pyrimidine analog from the series consisting of uracil, 

thymine, cytosine, 5-fluorouracil, 5-chlorouracil, 5-bromouracil, 
dihydrouracil or 5-methylcytosine. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

1, which has one of the following one of the following 
formulae IIIa, IIIb, IIIc or IIId  

 

 
wherein R
14
 is hydrogen or a radical which forms a 
nucleotide linking group and R
15
 is hydrogen or cyclohexylcarbonyl. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

20, wherein R
14
 is a phosphorus-containing radical of 
formula IVa, IVb or IVc 


 
which forms a nucleotide linking group, wherein 


Z is oxygen or sulfur; 
X, X' and X'' are each independently of one another oxygen  
 

or sulfur carrying a negative charge, with counterion Li, 
Na, K, Cs, tertiary or quaternary ammonium; or X' and X'' 

are each independently of the other C
1
-C
12
alkyl, C
6
-C
12
-aryl, 
C
7
-C
20
aralkyl, C
7
-C
20
alkaryl, -OR
b
 or -SR
b
; 
X''' is C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
-alkaryl, 
-OR
b
 or -SR
b
; and 
R
b
 is C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
alkaryl; 
R
18
 and R
19
 are each independently of the other hydrogen, 
C
1
-C
12
alkyl, C
2
-C
12
alkenyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl or 
C
7
-C
20
alkaryl;
 
and alkyl, aryl, aralkyl and alkaryl in R
18
, R
19
 and R
b
 
are unsubstituted or substituted by alkoxy, alkylthio, 

halogen, -CN, -NO
2
, phenyl, nitrophenyl or halophenyl. 
A process for the preparation of a nucleoside or 
nucleoside analog according to claim 1, which comprises 

reacting a nucleoside or nucleoside analog with tris4,4',4''-tert-butyltrityl 
chloride in the presence of a 

sterically hindered tertiary amine in a suitable aprotic, 
polar, basic solvent. 
A process for the preparation of an oligonucleotide 
of formula V 


5'OH(U)
m
(V)
n
OH-3'
 
wherein U and V are identical or different, natural or 

synthetic nucleoside residues and m and n are each 
independently of the other 0 or a number from 1 to 200, 

and the sum of m and n is 2 to 200, by 

(a) reacting a compound of formula VI 

R
20
-0-(U')
m'
(V')
n'
OR
21
-3'
 
wherein R
20
 is a protective group and U' and V' have the 
meanings of U and V, m' and n' are each independently of 

the other 0 or a number from 1 to 199, and the sum of m' 
and n' is 2 to 199, and R
21
 is a phosphorus-containing 
radical of formula IVa, IVb or IVc  

 

 
which forms a nucleotide linking group, wherein 


Z is oxygen or sulfur; 
X, X' and X'' are each independently of one another oxygen 
or sulfur carrying a negative charge, with counterion Li, 

Na, K, Cs, tertiary or quaternary ammonium; or 
X' and X'' are each independently of the other C
1
-C
12
alkyl, 
C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
alkaryl, -OR
b
 or -SR
b
; 
X''' is C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
-alkaryl, 
-OR
b
 or -SR
b
; and 
R
b
 is C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
alkaryl; 
R
18
 and R
19
 are each independently of the other hydrogen, 
C
1
-C
12
alkyl, C
2
-C
12
alkenyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl or 
C
7
-C
20
alkaryl;
 
and alkyl, aryl, aralkyl and alkaryl in R
18
, R
19
 and R
b
 
are unsubstituted or substituted by alkoxy, alkylthio, 

halogen, -CN, -NO
2
, phenyl, nitrophenyl or halophenyl, 
with a compound of formula VII 


5'-OH(U'')
m''
(V'')
n''
O-R
22
 
wherein U'' and V'' have the meanings of U and V, m'' and n'' 

are each independently of the other 0 or a number from 1 
to 198, and the sum of m'' and n'' is 2 to 198, and R
22
 is 

(i) a radical of formula IVb, wherein Z is oxygen or 
sulfur; X' and X'' are each independently of the other 

C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, C
7
-C
20
alkaryl, -OR
b
 
or -SR
b
; and R
b
 is C
1
-C
12
alkyl, C
6
-C
12
aryl, C
7
-C
20
aralkyl, 
C
7
-C
20
alkaryl, and alkyl, aryl, aralkyl and alkaryl in R
b
 
are unsubstituted or substituted by alkoxy, alkylthio,  

 
halogen, -CN, -NO
2
, phenyl, nitrophenyl or halophenyl; 
(ii) a hydroxyl protective group; or 
(iii) a linkage to a solid carrier material by means of 
a linker; 
(b) if desired, repeating step (a) until an oligonucleotide 
of the desired length has formed, and, before 

each coupling, removing the protective group R
20
, capping 
any free hydroxyl groups present, and then oxidizing the 

resultant phosphite to the phosphate, 
(c) if desired, detaching or isolating the oligonucleotide, 
and 
(d) removing the residual protective group R
20
, 
wherein the protective group R
20
 is TTTr. 
A process according to claim 23, wherein the sum of 
m and n is 2 to 50. 
A process acording to claim 24, wherein the sum of m 
and n is 2 to 30. 
Use of a nucleotide, nucleotide analog or oligonucleotide 
according to claim 1 for the preparation of an 

oligonucleotide of formula V 

5'-OH(U)
m
(V)
n
OH-3'
 
wherein U and V are identical or different, natural or 

synthetic nucleoside residues and m and n are each 
independently of the other 0 or a number from 1 to 200, 

and the sum of m and n is 2 to 200. 
A compound according to claim 2, wherein the amidine 
protective group is dimethylaminomethylidene. 
A nucleoside, nucleoside analog, nucleotide, 
nucleotide analog or oligonucleotide according to claim 

1, wherein the primary protected hydroxyl group is at 
position 5' of the parent structure.  

 
Use of the radical tris-4,4',4''-tert-butyltrityl as 
protective group for a primary hydroxyl group of the 

parent structure of a nucleoside, nucleoside analog, 
nucleotide, nucleotide analog or oligonucleotide comprising 

at least two such identical or different nucleotides 
and/or nucleotide analogs, whose parent structure comprises 

an unsubstituted or substituted residue of a 
nucleobase B and one primary hydroxyl group. 
Use according to claim 29, wherein the primary 
hydroxyl group is at position 5' of the parent structure. 
</CLAIMS>
</TEXT>
</DOC>
